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We report the use of axonal transport to achieve intraneural drug delivery. We 
constructed a novel tripartite complex of an axonal transport facilitator conjugated to a 
linker molecule bearing up to a hundred reversibly attached drug molecules.  The 
complex efficiently enters nerve terminals after intramuscular or intradermal 
administration and travels within axonal processes to neuron cell bodies. The tripartite 
agent provided 100-fold amplification of saturable neural uptake events, delivering 
multiple drug molecules per complex. In vivo, analgesic drug delivery to systemic and to 
non-targeted neural tissues was greatly reduced compared to existing routes of 
administration, thus exemplifying the possibility of specific nerve root targeting and
effectively increasing the potency of the candidate drug gabapentin 300-fold relative to 
oral administration. 
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INTRODUCTION
Pharmacological entrainment of axonal transport for the purpose of targeted drug 
deliver to selected sites is acknowledged as a highly desirable objective since it would 
allow for targeted antiviral, antineuropathic or regenerative treatments to segmentally 
selected ganglion or CNS cells. Methods using direct injection into nerves 
1
, introduction 
of modified neurotropic viruses 
2
, or delivery of neurotoxins such as tetanus toxin or ricin 
3,4
 have been explored but each pose barriers to routine clinical use. Phage display has 
been used to generate synthetic peptides to promote axonal transport 
5
, but it has not been 
clear how to exploit this.
Retrograde axonal transport of exogenous molecules from the periphery to CNS 
neuronal cell bodies is long established 
6
 and is one of the methodological bases for 
mapping neuroanatomical pathways
7-9
. The underlying physiology and biochemistry are 
increasingly well understood 
10-14
.  However, although axonal transport for drug delivery 
has been proposed previously 
15-19
, little or nothing is known about the major features of 
this biological system from the point of view of approaching it pharmacologically and 
there has been no agent demonstrated capable of accomplishing a clinical effect via this 
route. 
We designed a novel type of molecular complex to achieve this. The agents used 
are various forms of a tripartite complex composed of a first moiety acting as an “axonal 
transport facilitator” (ATF), an “amplifying polymer” (AP) second moiety acting to 
achieve amplification of the fundamental event of synaptic endocytosis by carrying along 
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multiple drug molecules with each saturable uptake event, and a third moiety composed 
of multiple copies of the therapeutic molecule, reversibly linked to the polymer (Fig. 1). 
We were able to administer a small intramuscular injection with 1/300
th
 of the 
usual oral dose of gabapentin (half life 8 hours) and achieve a degree of neuropathic pain 
suppression that could not be obtained with tolerable amounts of oral therapy while 
extending the half life of the drug by more than an order of magnitude.
MATERIALS AND METHODS
These are summarized in Table S-1 and presented in detail in the associated 
Supplementary Information that follows. 
RESULTS 
Results are summarized in table S-1
A. Chemical synthesis and stability
I – Chemical entities
[1]. Effective synthesis with loading sufficient for amplification
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The synthesis strategy achieved attachment of drug to at least 30% of dextran 
monomers for both gabapentin and valacyclovir. The 70,000 MW dextran has 
approximately 430 dextrose sub-units so each Wheat germ agglutinin (WGA) molecule 
endocytosed in these experiments delivered around 100 molecules of drug.
[2]. Particle based carriers can be delivered intraneuronally
EDTA washing of dextran coated magnetite particulates resulted in hydroxide 
free ferrites that were non-reactive and preserved their superparamagnetic properties 
during axonal transport. After conjugation of an axonal transport facilitator to the dextran 
coat, they were effectively endocytosed and transported intact despite their (10-15 nm)
size. 
II – Intracellular release and drug activation
[3]. The stability of a drug is maintained through chemical linkage and biological 
release
In the BHK viral plaque reduction experiments, free drug in the culture medium 
resulted in plaque reduction by 96% at a dose of 5 micrograms/well, but a dose of 50 
micrograms/well of the drug bound to dextran was required to achieve an equivalent 
effect.  However we observed nearly 100% plaque reduction using a dose of 5 
microgram/well of tripartite WGA-dextran-drug conjugate. This demonstrates that the 
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WGA efficiently promoted endocytosis of the tripartite agents while dextran-drug alone 
was not readily taken up by cells. 
On chemical grounds, the carboxyl links binding drug molecules to dextran 
should be hydrolyzed after endocytosis. For valacyclovir (pharmacologically inactive),
the product of the hydrolysis is free and active acyclovir.   Therefore, the antiviral effect 
of the tripartite confirms  release of acyclovir from the tripartite carrier  after endocytosis. 
B. Interactions with axon terminus and axonal processing
III. Effects of polymer, linker and drug
[4]. Effects of polymer size on tripartite uptake into nerves
10,000 MW dextran achieved more avid and rapid axonal uptake than 70,000 
MW dextran. Dextran 70K based material is taken up effectively but at a lower rate. With 
10K dextran, there is extensive uptake within ten minutes after application and washing. 
Similar levels of uptake are seen with 70K dextran after 60 minutes. However the 
differential efficacy of uptake was not large enough to outweigh the benefits of greater 
amplification of uptake events achieved by using the higher capacity larger molecules for 
drug delivery. Since molecular loading of the polymers was equivalent for various sized 
dextrans, the increased drug delivery with increased molecular size was linear. However, 
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the losses in uptake efficiency with larger molecules appeared to be much less than 
linear. The consequence is that although smaller dextran molecules were endocytosed 
more avidly and rapidly than 70K based vehicles, more drug molecules were still 
delivered by the 70K based vehicles.
[5]. Effects of charge on uptake and transport 
The overall charge of the complex had a large impact on efficiency of uptake 
(Fig. S-5). There was virtually no uptake into cultured neurons when the overall charge of 
the complex was negative, and effective uptake occurred when charge was neutral, or 
when overall charge was positive. 
[6]. Effects of side group mediated hydrophobicity on uptake and transport
Acylation of  FITC-labeled, WGA-conjugated dextran to make the molecules 
progressively hydrophobic led to complete failure of uptake and transport. We assessed 
various degrees of acylation and found that this effect occurred even at very low ratios of  
acylation.
IV – Effects of axonal transport facilitator
[7],[8],[9]. Efficacy of physiologic, non-physiologic and synthetic ATFs
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The Campenot chamber studies demonstrated similar efficacy for Nerve growth 
factor (NGF) and WGA for producing uptake of the tripartite carrying FITC (Fig. S-6).  
The phage display experiments demonstrated that novel purely synthetic ATFs could be 
discovered and then produced in vitro which not only had equivalent efficiency for 
neuronal uptake, but which could also be more efficiently sub-targeted to different types 
of neuronal populations (e.g. general sensory, pain, motor, autonomic). Blockage of 
movement of compounds with phage derived synthetic ATF by the use of axonal 
transport inhibitors confirmed that purely synthetic ATFs had been generated, identified, 
and produced.
V. Effects of intra-axonal processing
[10]. Survival of small chemical molecules linked to the tripartite
When WGA-dextran-gabapentin was used, cross staining with antibodies to 
gabapentin confirmed preserved antigenicity of the drug after axonal transport of the 
tripartite, although this method could not itself confirm that the drug was intact or active 
after transport and release. Dextran-gabapentin with no conjugated WGA did not produce 
detectable gabapentin antigenicity in the histological sections.
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[11]. Large molecule access to spinal cord from intramuscular injections
After small IM injections in muscle, WGA delivered sufficient quantities of 
functioning HRP enzyme to label numerous motorneurons (Fig. 2a, 2b, 2c) in our primate 
model. Enzymatic activity of the horseradish peroxidase survived any hypothetical 
lysosomal degradation during transport and yielded product distributed throughout the 
neuron. Both epaxial and hypaxial muscles proved an effective route to reach spinal cord 
quickly (several hours) with no apparent difference in delivery of intact enzyme via 
axons despite the difference in distance of transport. The labeled spinal cord motor 
neuron pool for these axial muscles had greater longitudinal extent among spinal cord 
segments than for appendicular muscles. These findings are consistent with previous 
reports concerning WGA 
20
 and NGF 
21
 and their intramuscular introduction  
22 23
.
The rate of transport appeared to be consistent with time scales predicted by 
literature values of 30-100 mm/day 
24
. Overall the area of spread of injectate was limited 
to a few millimeters, although the distribution in the epaxial muscle spinal cord 
motorneuron pool extended over several centimeters.
[12], [13], [14], [15]. Intact transport of targeted nanoparticles by intact axon 
termini
Electron microscopy showed appropriately sized ferrites within the axon, more 
than three centimeters from the WGA-dextran-Fe injection site (Fig. 4). The appearance 
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of the ferrites in endosomes was similar to what has been seen in studies of similar agents 
in other tissues 
25
, but in this case the particles were restricted to the axonal stream. The 
autoradiographic studies demonstrated sciatic nerve radioactivity and so provided similar 
evidence that the magnetite containing particles were transported in nerves.
The relaxivity experiments (Fig. S-4) taken together with distribution studies 
showing the concentration of magnetite delivered to the axon by the tripartite showed that 
the amount of magnetite transported should affect the T2 relaxation rate of nerve. The 
observation of a decrease of T2 relaxation time in nerves transporting superparamagnetic 
nanoparticles in both the micro-MRI nerve channel studies (Fig.  S-7) and in the high 
resolution MRI experiments (Fig. S-8) confirmed that the carrier particles were not 
degraded.  Any hydrolysis of the sub-domain sized particles would have eradicated their 
superparamagnetic effect on T2 relaxation time in nerve as transport progressed. The 
relaxivity effect far exceeded that which would result from free iron or ferritin at the 
doses administered.
The WGA-dextran-magnetite experiments in rabbits confirm other reports 
26
 that 
particles of 5-15nm are endocytosed and transported by intact nerve endings. Some 
studies have suggested that nerve injury is required for the transport of larger particles  
27
,
but this result suggests that intact neurons will indeed transport large (up to 15nm) multi-
molecular aggregates or “transport particles” after intramuscular injection when the 
particles are well solvated. 
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C. Targeting and pharmacological efficacy
VI. Clinical target access
[16], [17], [18], [19]. Targeted Access to Clinically Relevant Neuronal Sub-
populations
Intramuscular injection of the tripartite WGA-dextran-FITC produced labeling of 
alpha motor neurons in the ventral horn and autonomic neurons in the intermediolateral 
cell column (Fig. 2d, 2e). We also observed good filling of proximal sensory neuron 
processes (axons) in the dorsal root entry zone and in lamina I and II of the dorsal horn of 
the spinal cord (Fig. S-9). Injection of foot pad and multiple hind limb muscle each 
resulted in labeling of less than 50% of ganglion cells, but injection of both muscle and 
skin resulted in filling of nearly 90% of dorsal root ganglion (DRG) cells (Fig. 2f, 2g, S-
10). In clinical use, the objective will typically be to reach specific sub-populations rather 
than filling an entire ganglion per se, so these results support the expectation that a large 
fraction of cells in a e.g. a subpopulation innervating a single muscle or patch of skin can 
readily be reached. 
Cross staining with an antibody to peripherin showed that many of the DRG 
sensory neurons that were accessed were C-fiber nociceptor cells (Fig. 3a to 3f). This 
helps confirm that this method of delivery does reach a selected subset of nociceptors that 
correlates specifically with the selected site of injection. The ATF played a major role 
since no detectable fluorescence was observed when dextran-FITC without ATF was 
administered in these experiments.
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VII. Distinctive pattern of distribution relative to trans-vascular
[20]. Unique distribution with high fraction of drug reaching neuronal targets
In the whole body distribution studies with small calf muscle injections, 
concentrations of [
125
I]-WGA in ipsilateral peripheral nerve and dorsal root ganglia of 
segments supplying the sciatic nerve reached six times systemic concentrations (Fig. S-
11) and demonstrated saturability and transport time consistent with other reports 
28
.
Activity in spinal cord was less than in nerve or DRG but did reach twice systemic 
concentrations when higher concentrations of injectate were used. The greatest activities 
detected in other tissues were in liver and kidney and these apparently reflected 
metabolized iodine. There was no significant activity detected in contralateral nerve and 
DRGs nor in ipsilateral nerves, ganglia, or spinal cord related to cervical, thoracic, or
higher lumbar segments.    NGF showed less transport to spinal cord than was seen for 
WGA consistent with selective uptake of NGF by sensory and autonomic nerves. 
Detection of activity due to [
59
Fe]-WGA-dextran- at other systemic sites was even less 
than for WGA or NGF alone.
Considerable amounts of drug remained in the axon itself at the time points 
sampled. It is known that para-nodal complexes of Schwann cells at the Nodes of Ranvier 
can endocytose materials from the axoplasm 
29
 and this may account for a peri-axonal 
depot effect with drug being cleared to the para-nodal complexes and then subsequently 
being re-released. Further studies will be needed to clarify this issue. 
[21]. Site of injection retains high amount of injectate
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The regional view provided by the [
131
I]-WGA gamma camera studies 
demonstrates that the total amount of the injectate remaining at the site of injection is 
large when compared to the amount in the small volume of the nerve. In part, this reflects 
the fact that WGA adheres to muscle cell membranes 
30
 as well as being taken up by 
adsorptive endocytosis at nerve termini. This also explains a depot effect whereby 
additional amounts of the compound continue to be introduced into the axonal stream 
over a period of several days. 
[22]. Pharmacologically efficacious drug amounts were delivered
The tripartite assemblage with [
14
C]-labeled gabapentin produced activity levels 
for gabapentin in ipsilateral neurons of more than 600 times greater than background 
while counts remained at background levels in contralateral neurons. This demonstrated 
the localizing effect of injection of polymer-bound drug conjugated to an axonal transport 
facilitator, and also allowed us to estimate the drug concentration achieved based on the 
specific activity of the [
14
C]-labeled gabapentin. 
VIII – The pharmacologic effects of ATF mediated delivery are not 
obtainable by trans-vascular agents
[23]. Prolonged suppression of hyperalgesia 
In the hyperalgesia experiments a single injection with the tripartite agent  
reduced the hyperalgesia (p<0.05 in eight out of the nine comparisons of treatment versus 
control) for at least four days after injection (Fig. 5). The total dose was 0.375 mg/kg 
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using the novel intraneural transport method compared to 120mg/kg total dose orally for 
four days of the usual human oral dosing. Prolonged efficacy may have been due to a 
depot effect in muscle, slow redistribution from axon and Schwann cells to nerve cell 
body, slow clearance from inside the nerve, or preemptive blocking of newly produced 
receptor molecules en route from ribosome to cell surface. 
DISCUSSION
Gabapentin not only crosses the blood brain barrier but is subject to some active 
concentration 
31,32
. Therefore, clinically efficacious axonal transport for intraneural drug 
delivery would need to produce similar concentrations near the internal cell surface of 
accessed neurons. In this model, histological estimates of the ratio between the estimated 
intracellular volume of the accessed neurons (InCvol) and the actual volume of the entire 
dorsal root ganglion (DRGvol) provide a correction factor (InCvol/DRGvol) that allows 
for conversion of total DRG concentration into estimated intracellular concentration in 
the accessed neurons. 
 When these considerations were employed, our counts of delivered [
14
C] 
suggested delivery of gabapentin at intracellular doses equal to or greater than 100M. 
These in vivo [
14
C]-gabapentin studies therefore showed that this technology can deliver 
drugs to target neurons at pharmacologically efficacious doses using 1/300
th
 of the oral 
dose that would be required to achieve the same intracellular concentration in target cells. 
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In addition, this system resulted in a ten fold increase in effective half life relative 
to oral administration. This appears to be because of the unique dynamics of this delivery 
mechanism. This involves both a muscle injection site depot effect for the large tripartite 
complexes and a prolonged stream of delivery to the neuron from the axon and its 
associated paranodal complexes. 
In this set of experiments, neither systemic delivery of the agent by a 
subcutaneous route nor administration of free drug alone to the affected limb had any 
significant therapeutic effect. Although dextran can itself weakly promote axonal 
transport 
33
, the use of dextran/drug with no ATF showed only limited effect in 
occasional animals and was in no case statistically significant.  
It had not been clear in the past whether gabapentin, delivered via axonal 
transport, acts inside nerve cells or on the external cell surface  
34-36
.  Further, the 
conjugation reaction and subsequent release of the gabapentin might have converted it to 
a chemically distinct metabolite or residue. The high efficacy of this intraneurally 
delivered agent constructed with gabapentin demonstrates for the first time that delivery 
of a clinically efficacious small molecule therapeutic agent from inside the  cell via an 
intraneural route can achieve the same pharmacological effect as delivery from outside 
the cell via a systemic route.  This also corroborates recent evidence that the site of action 
of gabapentin is indeed intracellular 
37
.
Whilst there are additional  issues to resolve before axonal transport based 
medications come into regular clinical use their eventual development now seems 
realistic. Previously, the relatively small number of ‘uptake events’ per neuron for 
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molecules like NGF has limited their applicability for intraneural drug delivery. This 
work demonstrates that a linker carrying large numbers of drug molecules can amplify 
the pharmacological effect of each uptake event by at least two orders of magnitude. 
Amplification by an additional order of magnitude through alternative conjugation 
schemes appears to be readily achievable. 
We anticipate that intraneural pain medication will have a significant impact on 
the management of pain after surgery and in the treatment of patients suffering from 
intractable chronic pain unresponsive to existing pain medications. Some efficacious 
agents whose use is limited by systemic toxicity may be safely and effectively delivered 
by an axonal transport delivery vehicle. It is likely that anti-viral, neuroprotectant and 
anti-spasmodic agents (small molecule, peptide, or nucleic acid) can also be delivered to 
important locations in the nervous system in this manner. The application of this new 
class of intraneural pharmacologic vehicles also provides a novel tool in the investigation 
of a number of aspects of basic neurobiology. 
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Figures & Legends
Figure 1 – Tripartite delivery vehicle. 
(a)  The drug delivery vehicles include a targeting element – the axonal 
transport facilitator or ATF (blue sphere), and a polymer such as dextran (red 
repeating units) that carry multiple drug molecules (purple). (b) They are 
designed to be injected in muscle or skin and then travel via an “intraneural” 
route to deliver the drug molecules to the cell body.
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Figure 2 – Axonal transport to spinal cord neurons and dorsal root ganglion. 
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(a-c) Magnified, back illuminated view of an individual motor neuron in an 
oblique longitudinal section through a portion of the ventral horn of the spinal 
cord (Macaca fascicularis), and seen at lower magnification in figures b and 
c. The dark orange material seen inside the cell and filling the cell body and 
dendritic processes is the product of a chemical reaction carried out by an 
administered enzyme, horseradish peroxidase. To introduce this exogenous 
enzyme into the cell, it was conjugated to WGA, an ATF (axonal transport 
facilitator), then injected into a muscle innervated by the axons which arise 
from these neuron cell bodies.  (d)  Section of rat spinal cord showing 
retrogradely transported WGA-FITC in the motor neuron cell bodies (v) and 
in cells in the autonomic intermediolateral cell column (i). (e) magnified view 
of  motor neurons seen in (d). (f, g) Delivery to rat dorsal root ganglion cells 
from different peripheral sources. Section of L4 dorsal root ganglia showing 
retrogradely transported FITC (green) injected intra-muscular and TRITC 
(red) injected intra-plantar, in the sensory neuron cell bodies (fp – footpad 
injection, ga – gastrocnemius injection). Scale bars (a) = 50 m, (b) = 200m, 
(c) = 400 m (d) = 120μm, (e) = 30μm, (f) = 170μm, (g) = 45μm.
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Figure 3 –Demonstration of transport to C-type nociceptor cells in dorsal root ganglion. 
Section of rat L5 dorsal root ganglia showing retrogradely transported FITC 
combined with immunohistochemistry for the specific C-fiber nociceptor 
marker, Peripherin. (a) Retrogradely transported FITC, (b) the same field as in 
a showing cells that are immuno–positive for peripherin, (c) overlay of c and d 
showing FITC is present in the nociceptors (v – same neuron in a, b, & c). (d)
Two sensory neurons containing retrogradely transported FITC, a third neuron 
is unlabeled, (e) the same field as in c showing that all three neurons are 
positive for Peripherin, (f) overlay of f and g (^ - same neuron in d, e, & f). 
Scale bars (c-e) = 150μm, (f-h) = 40μm.   26 cells vs.  59 cells
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Figure 4 – Intra-axonal location of transported agents. 
(a) Electron micrograph of rabbit tibial nerve four days after injection of the 
gastrocnemius muscle with ferrite-WGA tracer. (b)  magnified view of a 
vesicle seen in (a) to 195,000x. (ly) lysosomal vesicle, (fp) small particles 
transporting on microtubules (mi), (ep) larger particles in vesicles.
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Figure 5 – Effect of gabapentin delivered by intraneural vehicle. The effect of 
Gabapentin tripartite administration, to mono-neuropathic animals, on thermal 
nociceptive threshold (con, contralateral; ips, ipsilateral; GPN, Gabapentin). 
Results are the mean ± SEM (n = 6). The difference between the ipsilateral 
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and contralateral side is significant from 4 days post surgery to the end of the 
experiment in all treatment groups. Treatment with Gabapentin tripartite to the 
injured limb caused a significant elevation in paw withdrawal latency which 
was evident within 2 days and lasted for a further 4 days, after which the 
latency returned to that of the other groups (e.g. day 12, P=0.0049 between 
Dx-GPN and GPN tripartite ipsilaterally). This effect was not observed in any 
other group.
A. Filler et al       -26- Intraneural Drug Delivery
References
1. Shubayev, V.I. & Myers, R.R. Axonal transport of TNF-alpha in painful 
neuropathy: distribution of ligand tracer and TNF receptors. Journal of 
neuroimmunology 114, 48-56 (2001).
2. Boulis, N.M., Willmarth, N.E., Song, D.K., Feldman, E.L. & Imperiale, M.J. 
Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector 
remote spinal cord gene delivery. Neurosurgery 52, 381-387; discussion 387 
(2003).
3. Bohnert, S. & Schiavo, G. Tetanus toxin is transported in a novel neuronal 
compartment characterized by a specialized pH regulation. The Journal of 
biological chemistry 280, 42336-42344 (2005).
4. Johnson, L.R., Westrum, L.E., Henry, M.A. & Canfield, R.C. Toxic ricin 
demonstrates a dual dental projection. Brain research 345, 379-383 (1985).
5. Federici, T., Liu, J.K., Teng, Q., Yang, J. & Boulis, N.M. A means for targeting 
therapeutics to peripheral nervous system neurons with axonal damage. 
Neurosurgery 60, 911-918; discussion 911-918 (2007).
6. Kristensson, K., Olsson, Y. & Sjostrand, J. Axonal uptake and retrograde 
transport of exogenous proteins in the hypoglossal nerve. Brain research 32, 399-
406 (1971).
7. Cowan, W.M., Gottlieb, D.I., Hendrickson, A.E., Price, J.L. & Woolsey, T.A. The 
autoradiographic demonstration of axonal connections in the central nervous 
system. Brain research 37, 21-51 (1972).
8. Kuypers, H.G., Kievit, J. & Groen-Klevant, A.C. Retrograde axonal transport of 
horseradish peroxidase in rats forebrain. Brain research 67, 211-218 (1974).
A. Filler et al       -27- Intraneural Drug Delivery
9. Nauta, H.J., Pritz, M.B. & Lasek, R.J. Afferents to the rat caudoputamen studied 
with horseradish peroxidase. An evaluation of a retrograde neuroanatomical 
research method. Brain research 67, 219-238 (1974).
10. Dahlstrom, A.B., Czernik, A.J. & Li, J.Y. Organelles in fast axonal transport. 
What molecules do they carry in anterograde vs retrograde directions, as observed 
in mammalian systems? Molecular neurobiology 6, 157-177 (1992).
11. DiStefano, P.S., et al. The neurotrophins BDNF, NT-3, and NGF display distinct 
patterns of retrograde axonal transport in peripheral and central neurons. Neuron
8, 983-993 (1992).
12. Vallee, R.B. & Bloom, G.S. Mechanisms of fast and slow axonal transport. 
Annual review of neuroscience 14, 59-92 (1991).
13. Schnapp, B.J. & Reese, T.S. Dynein is the motor for retrograde axonal transport 
of organelles. Proceedings of the National Academy of Sciences of the United 
States of America 86, 1548-1552 (1989).
14. Cyr, J.L. & Brady, S.T. Molecular motors in axonal transport. Cellular and 
molecular biology of kinesin. Molecular neurobiology 6, 137-155 (1992).
15. Haschke, R.H., Ordronneau, J.M. & Bunt, A.H. Preparation and retrograde axonal 
transport of an antiviral drug/horseradish peroxidase conjugate. Journal of 
neurochemistry 35, 1431-1435 (1980).
16. Bizzini, B., Grob, P., Glicksman, M.A. & Akert, K. Use of the B-IIb tetanus toxin 
derived fragment as a specific neuropharmacological transport agent. Brain 
research 193, 221-227 (1980).
17. Filler, A.G., et al. Intramuscular injection of WGA yields systemic distribution 
adequate for imaging of axonal transport in intact animals. Soc. Neurosci. Abs. 17,
1480 (1991).
18. Filler, A.G. & Bell, B.A. Axonal transport, imaging, and the diagnosis of nerve 
compression. British journal of neurosurgery 6, 293-295 (1992).
19. Filler, A.G. Axonal transport and MR imaging: prospects for contrast agent 
development. J Magn Reson Imaging 4, 259-267 (1994).
A. Filler et al       -28- Intraneural Drug Delivery
20. Schwab, M.E., Javoy-Agid, F. & Agid, Y. Labeled wheat germ agglutinin (WGA) 
as a new, highly sensitive retrograde tracer in the rat brain hippocampal system. 
Brain research 152, 145-150 (1978).
21. Hendry, I.A., Stockel, K., Thoenen, H. & Iversen, L.L. The retrograde axonal 
transport of nerve growth factor. Brain research 68, 103-121 (1974).
22. Brushart, T.M. & Mesulam, M.M. Transganglionic demonstration of central 
sensory projections from skin and muscle with HRP-lectin conjugates. . 
Neuroscience Letters 17, 1-6 (1980).
23. Kramer, M., Deacon, T.W., Sokoloff, A. & Filler, A. Organization of 
motorneurons innervating epaxial and hypaxial musculature in the frog, rat, and 
monkey. Soc. Neurosci. Abs. 13, 526 (1987).
24. Willard, M., Cowan, W.M. & Vagelos, P.R. The polypeptide composition of 
intra-axonally transported proteins: evidence for four transport velocities. 
Proceedings of the National Academy of Sciences of the United States of America
71, 2183-2187 (1974).
25. Weissleder, R., et al. Ultrasmall superparamagnetic iron oxide: characterization of 
a new class of contrast agents for MR imaging. Radiology 175, 489-493 (1990).
26. Philippe, E. & Droz, B. Calbindin-immunoreactive sensory neurons of dorsal root 
ganglion project to skeletal muscle in the chick. The Journal of comparative 
neurology 283, 153-160 (1989).
27. Colin, W., Donoff, R.B. & Foote, W.E. Fluorescent latex microspheres as a 
retrograde tracer in the peripheral nervous system. Brain research 486, 334-339
(1989).
28. Margolis, T.P. & LaVail, J.H. Further evidence in support of the selective uptake 
and anterograde transport of [125I]wheat germ agglutinin by chick retinal 
ganglion cells. Brain research 324, 21-27 (1984).
29. Gatzinsky, K.P. & Berthold, C.H. Lysosomal activity at nodes of Ranvier during 
retrograde axonal transport of horseradish peroxidase in alpha-motor neurons of 
the cat. Journal of neurocytology 19, 989-1002 (1990).
A. Filler et al       -29- Intraneural Drug Delivery
30. Barchi, R.L., Bonilla, E. & Wong, M. Isolation and characterization of muscle 
membranes using surface-specific labels. Proceedings of the National Academy of 
Sciences of the United States of America 74, 34-38 (1977).
31. Pan, C.F., et al. Inhibitory mechanisms of gabapentin, an antiseizure drug, on 
platelet aggregation. The Journal of pharmacy and pharmacology 59, 1255-1261
(2007).
32. Luer, M.S., et al. Saturable transport of gabapentin at the blood-brain barrier. 
Neurological research 21, 559-562 (1999).
33. Olsson, T. & Kristensson, K. A simple histochemical method for double labeling 
of neurons by retrograde axonal transport. Neuroscience Letters 8, 265-268
(1978).
34. Taylor, C.P., et al. A summary of mechanistic hypotheses of gabapentin 
pharmacology. Epilepsy research 29, 233-249 (1998).
35. Novelli, G.P. & Trovati, F. Gabapentin and neuropathic pain. The Pain Clinic 11,
5-32 (1998).
36. Maneuf, Y.P., Luo, Z.D. & Lee, K. alpha2delta and the mechanism of action of 
gabapentin in the treatment of pain. Seminars in cell & developmental biology 17,
565-570 (2006).
37. Hendrich, J., et al. Pharmacological disruption of calcium channel trafficking by 
the alpha2delta ligand gabapentin. Proceedings of the National Academy of 
Sciences of the United States of America 105, 3628-3633 (2008).
